Tag Archive for: Innovation Term Loans

How Innovation Finance Supports UK Product Development from Prototype to Launch

How Innovation Finance Supports UK Product Development from Prototype to Launch

/in /by

Product development in the UK consumes capital before revenue appears. Funding gaps slow iteration. Burn extends into quarters that were not budgeted for. Deadlines move. Management slows hiring. Innovation finance structures non-dilutive capital around defined milestones. Businesses continue delivery without compressing runway or surrendering ownership.

Innovation-led SMEs face timing pressure against committed spend. Engineering hires and tooling deposits fall due before sales validate the model. Validation costs follow. Finance must plan around those commitments. Structured funding links capital to build and testing phases. Development continues without unnecessary pauses.

Why Do Product Development Cycles Create Capital Pressure?

Product roadmaps create cost spikes. Prototyping concentrates engineering salaries and specialist components into short periods. Testing adds lab fees and certification costs. Contractors increase spend when internal capacity drops. Tooling deposits and manufacturing setup require payment before orders convert.

Spend follows milestones. It does not follow smooth monthly patterns. Funding demand peaks during validation and build stages. If funding lags, management defers hires. Product leaders narrow test scope. Delivery shifts into later quarters. A delayed test window can move an entire release cycle.

Technical requirements dictate timelines. Compliance standards dictate timelines. Supplier lead times dictate timelines. Engineering leaders cannot adjust those constraints. Finance must structure around them.

How Can Innovation Finance Support Early-Stage Prototyping?

Prototypes determine feasibility. They influence valuation. They require concentrated engineering time and specialist materials. Iteration increases engineering cost. Innovation finance funds build cycles without forcing immediate equity raises.

Funding pressure rises when prototype revisions extend engineering time. Supplier demands for upfront payment add further strain. Contractor invoices against short milestones accelerate spend. These costs stack quickly.

Businesses that structure funding in advance maintain engineering momentum. They validate proof of concept without interruption. Leadership enters valuation discussions with stronger positioning.

SPRK’s Innovation Grant Loans provide advance funding against approved grant milestones. Businesses repay those facilities from grant receipts. This structure protects ownership while supporting delivery.

How Can Product Teams Fund Iteration Without Slowing Development?

Testing rarely proceeds to schedule. Engineering teams miss performance thresholds. Compliance reviews introduce further requirements. Safety standards add testing rounds. Each extension increases burn.

Without structured funding, iteration fragments. Contractors pause. Engineers shift focus. Roadmaps extend.

Predictable capital reduces funding interruptions. Stable funding supports continuous validation. Engineering teams close testing loops faster when funding interruptions decrease.

How Can UK Businesses Fund Product Launch Without Equity Dilution?

Launch creates another funding spike. Tooling deposits increase working capital demand. Minimum order quantities require upfront commitment. Regulatory approval consumes time and cost. Marketing spend begins before revenue scales.

Short-term equity raises dilute ownership. They reduce flexibility before scale. Innovation finance can fund that phase.

  • SPRK’s Innovation Term Loans provide non-dilutive capital with structured repayments over an agreed term. These facilities support working capital across the launch period. Management gains visibility over repayment schedules. Leadership plans recruitment and supplier commitments with greater certainty.
  • SPRK’s R&D Tax Credit Loans provide advance funding against expected claims. Businesses repay these facilities when HMRC processes the credit. This structure can reduce short-term working capital pressure during launch.

How Should Innovation Finance Align with Product Development Milestones?

Finance teams must model expenditure by phase. They must test sensitivity against timeline shifts. Revenue assumptions require scrutiny. Weak assumptions distort funding requirements.

A two-month testing extension on a £150,000 monthly burn rate increases funding needs by £300,000. Planning must account for that additional cost. If it does not, leadership may raise capital under pressure.

Finance leaders should map salary cost by milestone. They should model validation extensions against runway. They should coordinate grant, tax credit and term facilities within one funding envelope. They should stress test hiring plans against conservative forecasts.

When capital mirrors the roadmap, recruitment aligns with technical need. Leaders sequence work according to delivery priorities. They avoid reacting to short-term cash gaps. Providers such as SPRK can structure facilities together to reflect actual spend patterns.

How Can Innovation Finance Maintain Financial Stability During Launch?

Faster delivery requires tighter financial control. Leadership must track runway, supplier exposure and obligations within a clear repayment framework.

Non-dilutive innovation finance can extend runway. It can support validation cycles. It can reduce repeated equity discussions. Structured facilities help leadership execute without rushed funding decisions.

When Should Product Teams Consider Innovation Finance?

Leadership should assess funding before commitments harden. Employment contracts reduce flexibility. Tooling deposits reduce flexibility. Delayed evaluation weakens leverage.

Common trigger points include:

  • Entering intensive prototype build phases with defined salary commitments
  • Securing specialist hires tied to technical milestones
  • Commencing extended certification or regulatory testing
  • Preparing for manufacturing deposits or minimum order quantities

Early structuring improves negotiating position. It reduces reactive funding decisions.

Structuring Capital Before Pressure Builds

Technical discipline alone does not protect delivery. Capital discipline determines sequencing. Funding delays force rushed operational decisions.

Clear funding structure reduces that pressure. Accurate burn modelling informs repayment design. Structured facilities support milestone execution.

If your roadmap includes significant prototype, testing or launch expenditure in the coming quarter, review runway sensitivity now. SPRK structures innovation term loans, grant loans and R&D tax credit facilities around live product roadmaps. That structure can support development without unnecessary dilution or disruption.

To discuss how your funding profile aligns with your milestones, contact the SPRK team.

How Venture Debt Fits Between Equity Rounds in a Tough Market

How Venture Debt Fits Between Equity Rounds in a Tough Market

/in /by

Founders now raise equity more slowly in a more selective market. Investors want stronger metrics and clearer paths to profit before they back the next round. For founders and finance leaders, the question is simple:

How do we reach the next value milestone without raising equity too early on weaker terms?

For some high-growth companies, this type of debt is part of the answer. Venture debt is most useful for VC-backed teams with predictable revenue that want to extend runway between equity rounds without immediately raising more capital. Used well, it sits between equity rounds and supports expansion without changing the cap table overnight. Used poorly, it adds pressure to a business that still needs to fix its model. If you are responsible for the runway tab in the model or the next board pack, this is the decision you are weighing.

What is the economic backdrop behind venture debt’s rise?

Higher interest rates and more caution from investors mean fewer speculative deals. Capital tends to flow to companies with proven revenue and a record of meeting targets. At the same time, many later-stage businesses still see specific opportunities to grow.

This mix of selectivity and opportunity helps explain why this kind of facility features more often in conversations between founders and CFOs. Lenders prefer companies that already show stable subscription or transaction income. Borrowers want to avoid raising equity on terms that do not reflect the progress they expect to make.

This type of debt becomes a way to continue executing while markets reset and to plan how you use time between rounds.

How does venture debt fit between equity rounds?

To understand the role of venture debt, look at the period between rounds in stages rather than as isolated funding events.

Stage 1: Immediately after an equity round

Shortly after an equity raise, the company has fresh capital and a clear plan for the next 18–24 months. At this point, this facility can increase available funding alongside the round.

Because investors have just committed money, the risk to a lender is lower. The company has runway and a board-approved plan backed by recognised funds. A facility like this in this stage can fund incremental projects, such as launching in one more market or accelerating a particular product initiative, without returning to the market for more equity.

Stage 2: Mid‑runway, during execution

As the business moves through its plan, reality diverges from the original model. Some projects outperform and some take longer than expected. Mid‑runway is often when management can see the next key milestone more clearly.

At this point, this facility can:

  • Extend runway beyond the original plan
  • Fund hires in sales, marketing, or customer success and support working capital needs linked to larger contracts or new geographies

The loan should not act as general buffer. It should fund initiatives that have already shown results and require additional capital.

Stage 3: Approaching the next raise

As the end of runway comes into view, boards and founders start to plan the next equity round. They review their metrics and decide how much progress they need before they meet new investors.

If founders use it carefully at this stage, a facility like this can create space to reach a stronger set of figures.

For example, a business may need a few more quarters of renewal data or time to bed in new pricing. A loan can support that period so that the next round is based on evidence rather than forecasts alone. The company enters equity conversations with more predictable results and a stronger position.

How does SPRK approach venture debt?

At SPRK, our version of venture debt uses innovation term loans that sit between R&D‑linked finance and traditional venture debt. These fixed term facilities work alongside products such as R&D tax credit and grant advance loans and give boards another way to fund innovation work between rounds.

How does SPRK’s version of venture debt work?

SPRK offers a structured form of venture debt that bridges the gap between traditional facilities and innovation‑linked finance. It provides fixed‑term funding for companies that have progressed beyond early R&D work but still want non‑dilutive capital between equity rounds. You can read more about how SPRK approaches venture debt on the Innovation Term Loans page.

Who does venture debt really suit?

Venture lenders focus on companies that can provide evidence rather than projections alone. They want to see recurring income, stable or improving unit economics, and a board that has managed growth capital before.

What venture lenders look for

Typical criteria include:

  • High proportion of recurring or contracted revenue
  • Clear records of customer retention and churn
  • Reasonable gross margins for the sector
  • A track record of meeting or explaining variances to plan
  • Supportive existing investors who understand debt

They also expect a finance function that can produce timely reports, forecast cash with reasonable accuracy, and manage covenant compliance. That might be a full-time CFO, a seasoned financial controller, or a fractional adviser.

Which business models benefit most from this kind of funding?

These facilities often suit:

  • B2B SaaS and software platforms with subscription income
  • Data and infrastructure providers with contracted usage
  • Fintechs and payment businesses with steady volumes
  • Healthtech and regulated services with long sales cycles but reliable renewals

In each case, lenders can look at revenue quality and renewal patterns to assess risk. The company has enough history to make forecasts meaningful.

When is venture debt the wrong funding tool?

Many companies should avoid venture debt when they:

  • Have not yet reached product‑market fit
  • Rely heavily on a small number of customers with short contracts
  • Cannot show a path to servicing the facility from income or a planned round
  • Lack the internal capacity to manage lender reporting and monitoring

In these situations, taking on debt can increase pressure on the team and limit the options available to them. The priority may need to be refining the offer, stabilising income, or securing more flexible capital.

What are the strategic advantages of using venture debt?

When the fit is right, this funding can give your company several clear advantages.

Extend runway without immediate dilution

The most obvious benefit is added runway. Instead of raising a new equity round as soon as cash levels fall, the company can draw on venture debt to fund specific uses. The shareholding structure does not change at the point of signing, and existing owners keep their positions while they work towards the next milestone.

Support focused growth initiatives

This funding can support clearly defined projects that improve the company’s profile before the next raise. Examples include:

  • Building a direct sales team in a new region once early pilots have succeeded
  • Expanding customer success and onboarding to lift retention and increase average contract value

These moves can improve the metrics you present and make equity conversations easier.

Strengthen negotiating position

A company that can show twelve to eighteen months of runway and steady growth often negotiates better equity terms than one that is raising in a hurry. A facility like this can provide that flexibility. It reduces the pressure to accept the first offer and lets the team choose investors who align with their long‑term plan.

How do you decide if venture debt is right for your company?

You do not need a long checklist to answer this. For most founders and CFOs, three questions are enough:

  • Can we show lenders predictable revenue and stable core metrics?
  • Does this capital help us reach a specific milestone that will improve our next equity round?
  • Can we service and repay the facility from operating cash flow and a realistic funding plan?

If you cannot answer yes to these points with current information, you may be better served by refining your model or considering other options before you add debt.

Considering other ways to fund innovation work?

If your delivery plan relies more on R&D work or innovation grants than on broad recurring revenue, it may help to review how SPRK’s R&D Tax Credit Loans and Innovation Grant Loans work before you commit to any debt facility.

Where innovation finance fits when venture debt is not suitable

Some companies decide that this form of debt does not fit their stage, risk profile, or revenue mix. In those cases, innovation finance can still help them fund planned work without moving straight to a new equity round.

If your company runs qualifying development and expects to claim R&D tax relief, an R&D tax credit loan can bring forward part of that expected credit to support active projects. SPRK explains this route on the R&D Tax Credit Loans page and provides an R&D Eligibility Checker so you can review your position before you speak with advisers or lenders.

If you hold or plan to apply for innovation grants, grant advance funding can finance project costs while you wait for claims to pay out. The Innovation Grant Loans pages describe how grant advances work, how the Grant Eligibility Checker helps you assess eligibility, and how open innovation grant programmes interact with this form of finance.

Where you want a fixed term facility linked to innovation work rather than a structure like this, innovation term loans can offer an alternative. SPRK sets out how these loans work on the Innovation Term Loans page so that boards and finance leaders can compare this option with other forms of funding.

Bringing it together

More founders and CFOs now discuss venture debt as funding markets tighten, but it still functions as a specialist tool. It works best for high‑growth companies with strong recurring income and credible investors who share a clear plan for the period between equity rounds.

Used carefully, it can extend runway and support focused growth so that you return to equity markets in a stronger position. Used without that discipline, it can add strain to a company that still needs to stabilise its model.

If you want to discuss funding options or review whether a facility like this fits your plan, you can speak with the team via SPRK’s contact page.

This article is for general information only and does not constitute financial, legal, or tax advice.

 

Why Innovation Finance Helps Scale R&D Without Dilution

Why Innovation Finance Helps Scale R&D Without Dilution

/in /by

Scaling R&D stalls when cash arrives at the wrong time. UK innovators often face a gap between delivery and when HMRC or grant payments land. Innovation finance keeps programmes moving without dilution by funding people, POs and test runs against hard dates such as payroll cut-offs, supplier lead times and booked pilot windows. SPRK Capital is a non-dilutive lender for UK SMEs, backed by a £20 million facility from British Business Investments. Innovation finance remains central to our approach, ensuring that every funding solution aligns with the pace and structure of active R&D projects. We fund against real artefacts, such as grant offer letters, profiled R&D claims, approved POs and a 13-week cash-flow, and we size facilities so drawdowns match when costs fall.

What Does Innovation Finance Mean for Scaling R&D?

Innovation finance aligns capital to R&D timing. Instead of waiting for lump-sum receipts, you use non-dilutive tools such as R&D tax credit loans, grant advances and innovation term loans to bridge milestones, keep teams in place and protect ownership.

Which innovation finance tool fits your next R&D milestone?

Innovation finance offers multiple routes to bridge gaps and maintain delivery continuity.

Use tax-credit loans before HMRC payment, grant advances between milestones, and term loans when scaling beyond R&D into pilots and commercialisation.

When should you use an R&D tax credit loan?

When you need to fund sprints, deposits, or payroll before an expected R&D credit lands.
Use an R&D tax credit loan when your project plan depends on costs you will recover through the R&D incentive but cannot defer. Typical examples include keeping engineering teams intact, placing component orders with long lead times, or running trials before a regulatory submission. A loan advances a proportion of your expected credit and aligns repayment to HMRC’s timeline, which keeps your forecast clean and predictable.

We advance a proportion of the verified credit and align repayment to the expected receipt. That keeps the cash‑flow forecast honest and your sprint plan intact. You keep equity, maintain delivery pace and avoid the indirect costs of delay. Learn more on R&D Tax Credit Loans.

Underwriting view: we size facilities against a verified R&D credit forecast and your cash runway; we typically lend up to 80% (70% for first-time borrowers), secure a first-ranking debenture, and we don’t lend where HMRC debts exist. Decisions follow quickly once information is complete.

How can a grant advance keep your milestone on track?

It bridges arrears-based or slipped Innovate UK payments, so acceptance isn’t missed.
Innovate UK and similar programmes often pay in arrears or by milestone. Even a small slippage can push a payment out, yet suppliers and staff still need to be paid. Grant advance funding fills this gap so you can meet deliverables and evidencing requirements on time. It keeps your schedule intact when dates move and procurement windows are tight.

You retain control of scope and timing, and you keep the team focused on delivery. If a milestone moves, an advance can cover the period until your claim clears. We match drawdowns to the actual costs you must meet to reach acceptance, such as deposits and lab time, so the claim paperwork stays clean. Read more on Innovate UK Grant Funding.

Underwriting view: we can advance up to 80% of each quarter or milestone on day one, you need to show you can fund the non‑grant share, and we secure a first‑ranking debenture.

When do innovation term loans make more sense than equity?

When you’re funding pilots, certifications, or early go-to-market without giving up ownership.
As you approach commercialisation, the funding needs evolve. You may need to scale headcount in sales or technical support, complete regulatory testing, or run pilot deployments with early customers. Equity can be a useful tool for long‑term scale, but it dilutes ownership and may not be the right fit before key value inflection points. An innovation term loan can supply working capital for this stage, matched to an agreed plan and reporting cadence. We agree dated milestones and reporting up front so funds track progress, not promises.

Term loans extend runway without giving up control. They can be used alongside the other tools described above, provided the use of proceeds is clear and the cash profile supports repayment. We agree a reporting cadence up front so variance is visible early. See Innovation Term Loans for detail.

Underwriting view: we size the facility from your latest R&D claim (up to 150%), set fixed repayments over up to 36 months, allow prepayments from future credits that reduce monthly payments, and do not charge early‑repayment fees.

Why does timing beat traditional options when you’re scaling R&D?

Innovation finance provides an agile bridge between scheduled milestones and incoming payments, helping companies maintain delivery momentum.

Traditional loans rely on assets and trading history, and equity takes time and dilutes ownership. Innovation finance aligns drawdowns and repayments to HMRC or grant cash‑in and to milestone triggers. That reduces management time spent on cash juggling and keeps the roadmap intact.

Example: you expect a £250,000 R&D credit in roughly 90 days. You draw £150,000 now to complete two sprints and supplier deposits, then clear the facility on receipt.

If dates move, we rebase against an updated Gantt, burn and supplier confirmations to reach the next acceptance point without freezing hiring or cancelling test slots.

Why does BBI’s £20m facility matter to your programme?

SPRK has a £20 million facility from British Business Investments. Practically, that means dependable capacity for eligible drawdowns, lender‑grade governance on decisions, and a partner who can scale the facility as your programme scales.

If you want the background, visit Working with British Business Investments.

How do you access innovation finance for your R&D programme?

Innovation finance at SPRK Capital is structured for clarity and speed, built around the documentation you already produce for HMRC or Innovate UK.

Start with an eligibility discussion and share three things: your latest 13‑week cash‑flow and management accounts; evidence for your claim or grant (offer letter with annexes, profiled R&D workings, last accepted claim); and your next 90‑day plan (Gantt or sprint schedule). We assess and size the facility against real dates. Once approved, drawdowns are scheduled against your plan and repayments align to your R&D credit or grant receipt, or the agreed term‑loan profile.

Costs are transparent and documented in your agreement. There are no early repayment fees. You receive responsive support from a team that works with innovative SMEs every day.

Turn your next milestone into measurable progress

Your R&D plan already defines the deliverables, costs, and timing. The right funding partner simply aligns to it, which ensures your teams keep moving, suppliers stay paid, and ownership stays yours.

Line funding up with your next acceptance point! Share your 13‑week cash‑flow, grant letter or profiled claim and the next 90‑day plan. We will size a non‑dilutive facility against real dates and confirm drawdown timing. Contact the team.

 

Scale with Non Dilutive Funding and Keep Your Equity

/in , /by

You’ve built something customers want. The roadmap is real, the next milestone has a date, and the team can execute. What you don’t want is to sell another percentage point just to cover hiring, parts, or supplier deposits.

Non dilutive funding is capital you can use to scale without giving up equity, typically grants, R&D tax credit advances, innovation loans, and revenue‑based facilities. If the roadmap slips, acquisition costs compound and the next round gets harder; the right non‑dilutive facility prevents that slide.

This guide shows how to finance the next 90–180 days with UK options: grants and grant advances, R&D tax credit advances, revenue‑based facilities, and Innovate UK innovation loans. We explain fit, sizing, and what to prepare so underwriting is quick. This guide to non dilutive funding covers the UK options founders use.

SPRK Capital is institutionally backed, including a £20 million facility with British Business Investments, which gives us the capacity and reliability high‑growth teams expect when timing matters. If you’re actively exploring non dilutive funding to hit your next milestone, you’re in the right place.

What problem are you solving right now?

Strong funding decisions start with a single sentence you can defend in front of your board. Are you bridging a timing gap while you wait for HMRC or a grant payment? Are you scaling what already converts, such as new hires, parts, and go‑to‑market, without slowing the roadmap? Or are you buying time to reach a stronger valuation before the next equity round? When we advise teams, we won’t discuss products until that job is clear. Once it is, the instrument usually picks itself.

Here’s how the main options map to real situations, with the operational context we look for when we underwrite.

Are grants (and grant advances) right for milestone‑driven projects?

Grants work when your programme has clear scope, milestones, and defrayal rules. As a form of non dilutive funding, a grant advance brings cash forward, so suppliers start on time. Most issues are timing, not eligibility.

Do it well:

  • Lock milestones and evidence before you draw.
  • Reconcile invoices and bank statements without manual fixes.
  • Draw close to when you place POs to avoid drift.

Smart & Horizon: Innovate UK paused Smart Grants in Jan 2025 and is running targeted pilots; check call‑specific competitions. UK applicants remain eligible for Horizon Europe calls through association, with opportunities to 2027.

How this helps your business: you keep suppliers moving on milestone dates and cut the true cash cost of R&D.

R&D advance vs. Innovation Term Loan: an R&D advance funds against an expected claim; the SPRK Innovation Term Loan is a 36‑month facility sized up to 150% of your latest R&D tax credit, with fixed repayments that HMRC prepayments can reduce.

Prefer to talk it through? Contact the SPRK team for a quick sense‑check.

How do R&D tax credit advances work in practice?

With a well‑evidenced claim, an R&D advance turns future relief into working capital. This non dilutive funding route keeps hiring and POs on schedule while HMRC processes the claim. From April 2024, claims sit under the merged RDEC scheme with a 20% expenditure credit. If you are loss‑making and R&D‑intensive (≥30%), ERIS can increase the net benefit (with a grace period if you met the threshold in the previous year). Keep the PAYE/NIC cap in mind (£20,000 + 3× relevant PAYE/NIC).

Size it safely: model base/high/low outcomes and anchor to the low case; confirm PAYE/NIC headroom; keep the AIF tight (uncertainty, advance over baseline, mapping from costs to activities).

How this helps your business: you convert a defensible claim into cash now, so delivery stays on track.

Is revenue‑based financing a fit for our cash cycle?

RBF suits predictable revenue and healthy margins. It is another non dilutive funding option for teams with repeatable sales. Repay a % of monthly revenue until a fixed total is reached. Underwrite to your trough month and compare on all‑in cost to maturity.

When it works: use it for paid acquisition with payback inside term, short cash conversion inventory, and repeatable channel spend.

When not to use it: if payback sits beyond the term or margins are thin, RBF strains cash flow.

Example: Facility £250k × 5% of revenue; trough month £300k ⇒ worst‑case repayment £15k.

How this helps your business: fund near‑term payback while protecting working capital in slower months.

When should we choose an Innovate UK innovation loan?

Choose an innovation loan for late‑stage R&D with a route to customers. This non dilutive funding option supports larger programmes over multiple years. Rates and terms vary by competition; UKRI examples show fixed rates (e.g., 7.4% p.a.) with part payable and part deferred interest during the project phase, then repayments later. When HMRC pays your R&D credit, you can apply that prepayment to reduce remaining instalments on the 36‑month SPRK Innovation Term Loan.

Plan for decision timelines and run a parallel path by lining up a grant or an R&D advance so work keeps moving. Sequence the instruments to reduce timing risk without dilution.

When not to use it: If you can’t evidence late‑stage development with a route to customers, apply later or use shorter‑term facilities first.

How this helps your business: you fund late‑stage development on a multi‑year schedule and lower monthly outflows when HMRC prepayments arrive.

Two quick scenarios

SaaS (MRR ~£150k): Use a compact RBF line for paid channels and an R&D advance for 2–3 months of product salaries to hold release dates.

Hardware/Deep Tech: Fund late‑stage development with an innovation loan and draw grant advances at milestone windows; use an R&D advance if lead times slip.

With the options on the table, choose based on speed, total cost to maturity, friction, and control. Here’s how that plays out.

Which non dilutive funding option should I choose?

Quick chooser:

  • Pick a grant advance if your work is milestone‑based and you need suppliers moving before reimbursement.
  • Pick an R&D advance if your evidence is complete and you’re bridging to HMRC payment while keeping the build on schedule.
  • Pick RBF if payback is inside the facility term and revenue is predictable enough to underwrite to the trough month.
  • Pick the SPRK Innovation Term Loan when you want multi‑year predictability sized to your latest R&D claim (with instalments that can fall as HMRC pays).

Want details on our 36‑month Innovation Term Loan? See our non dilutive funding page.

Still between options? Share your milestone and latest R&D claim; we’ll price an R&D advance and a 36‑month Innovation Term Loan side by side so you can pick the cleanest path.

What will a lender ask for to move fast?

For non dilutive funding decisions, bring a clean pack so we can move quickly:

  • Management accounts and a 12‑month forecast
  • 3–6 months of bank statements and AR/AP ageing
  • R&D pack (AIF, narratives, cost summaries, apportionment, PAYE/NIC)
  • Relevant grant letters and milestone schedules

Add months of runway without selling a share

We size to your low case and show the impact on cash in the next 90 days. If you want non dilutive funding that preserves ownership and momentum, follow the steps below.

Here is the fastest route:

  1. Share four numbers: your latest R&D tax credit estimate, cash at bank, average monthly net burn, and any overdue PAYE/NIC. If you’re exploring the Innovation Term Loan, include your latest filed R&D claim.
  2. Flag constraints: tell us about any existing charges or debentures so we can size and structure correctly.
  3. Upload evidence: your AIF (if drafted) or a claim‑pack summary, plus grant award letters and milestone schedules if you plan to combine products.
  4. Pick the product: we will price an R&D advance and a 36‑month Innovation Term Loan side by side so you can choose the cleanest non‑dilutive path.

If you prefer a quick sense‑check first, send these details by reply and we’ll confirm fit before paperwork.

 

How to Raise Money Without Selling a Piece of Your Business

How to Raise Money Without Selling a Piece of Your Business

/in /by

For UK founders and finance leaders who want growth capital without dilution
You can compare angel investment with non‑dilutive funding and choose the route that fits your plan and preserves control. This guide explains how angels work and sets out SPRK’s equity-free options, so you can fund growth and keep your cap table clean.

How can I raise capital and keep 100% ownership?

Use non‑dilutive funding. Finance qualifying development with an R&D tax credit advance, bridge awarded grant cash with a grant advance, or deploy proven solutions with innovation term loans with fixed repayments so you can move at pace. Choose the path that fits your stage and cash flow plan.

What does “non-dilutive” cover?

Non‑dilutive funding lets you raise money without issuing shares. You keep ownership and repay from future cash flows or from confirmed sources such as HMRC R&D credits or grant drawdowns. At SPRK, most situations fit one of three routes: R&D tax credit advances, grant advances, and innovation term loans.

How does angel investment work and what do you trade?

Angel investors provide capital in exchange for a minority stake. Many bring experience and mentoring. The trade‑off is dilution and another voice at the table. You prepare a pitch, then negotiate valuation and due diligence, and you live with the terms you agree. Angels can be a strong fit when you want sector guidance or when you can use their network to unlock key customers. They are less attractive if control and ownership matter more to you than advisory support.

Angels often ask for a short monthly update and a quarterly review pack.

Dilution changes control: you add a voice to key decisions and share more of the future upside.

Decision frame: If you want capital plus mentoring and you accept dilution, evaluate angels. If you want capital without dilution and a predictable repayment profile, evaluate non‑dilutive routes.

Your grant letter lands on Monday; your vendor deposit is due Friday. A grant advance covers the gap so delivery starts on time and your equity plan stays intact.

Which non‑dilutive funding option fits my plan?

When should I use an R&D tax credit advance?

Use this for in‑house development or qualifying automation/AI work. You unlock a portion of your expected HMRC R&D credit so your team can keep shipping while the claim completes. Align drawdowns to sprint plans and documentation. Keep an engineering log (tickets, commits, time). It speeds claim prep and underwriting.

Illustrative example: A team saves £1,050 per month in productivity while repayments are £700 per month. Net +£350 per month. Illustrative only. Your figures will vary by project, savings and terms.

Learn more: Fuel Your Scale‑up Strategy with R&D Advance Funding.

When should I use a grant advance?

Use this when you have an Innovate UK grant or a similar award and milestone timing creates cash gaps. A grant advance brings forward part of the award so you can fund deposits and hit deliverables on time. Keep evidence tight and maintain your reporting cadence. Attach the award letter ID and the milestone schedule to your request. Vendors respond faster when deposits are funded.

Illustrative example: A project has a £150k award with 40% due to suppliers before the first drawdown. An advance covers deposits so the schedule holds. Example figures. Your numbers will depend on the programme and terms.

Learn more: Why Grant Advance Funding is Important for Early‑Stage Innovations.

When should I use an innovation term loan?

Use this when you want fixed instalments and quick deployment for cloud migrations, cybersecurity, or SaaS tooling. Set the term to your expected savings and adoption. This route works well if grants don’t fit and R&D scope is limited. Baseline unit cost today and again at month three. Show the delta in your board pack.

Illustrative example: A company expects £1,400 per month in hosting and admin savings and repays £1,000 per month. Net +£400 per month; coverage 1.4×. Illustrative example. Actual savings and terms will differ.

Learn more: Innovation Term Loans.

Angel or non‑dilutive: which fits my situation?

Start with the outcome you want: guidance or control.

You want your angel’s sector intros to land this quarter. You also have a grant milestone in six weeks. Blend the two: use a grant advance to hold delivery dates while you close the round. If you need sector mentoring or early customer introductions, angel investment can help. If you hold a grant award or you are preparing an R&D claim, non‑dilutive funding often delivers capital faster and keeps equity unchanged. If your savings cover repayments with room to spare, an innovation term loan keeps delivery simple.

Example: £800 in monthly repayments vs £1,180 in monthly savings gives 1.48× coverage. Boards care more about that ratio than the label on the funding.

For advanced questions, reach out to an SPRK consultant and we’ll talk it through.

What’s the step-by-step to secure non-dilutive capital?

  1. Check what’s eligible and when cash arrives. Gather your grant letter (if relevant), your R&D status, and a delivery plan with dates.
  2. Select the route. Use the cues above to choose an R&D advance, a grant advance, or a term loan.
  3. Stress-test cash flow and coverage. Compare projected savings or receipts to repayments. Aim for net‑positive within a quarter, if your forecast supports it.
  4. Package your evidence and apply. Line up a project plan, supplier quotes, and a 13‑week cash flow view. That helps underwriting progress quickly. Include statements of work (SOWs) and your grant letter ID if applicable.

Capture three numbers for your board: breakeven month, repayment coverage (savings/repayments), and runway change.

Why pick SPRK for equity-free capital?

British Business Investments has committed £20m to SPRK. That backing helps us support founders and finance teams through delivery. Read the announcement and learn how we are working with BBI.

Raise without selling equity: what to do now

If you want capital without selling a piece of your business, start with non‑dilutive funding and map the route that fits your plan. If you already have milestones and budgets, contact us and we’ll match your plan to an R&D advance, a grant advance, or an innovation term loan.

Want a second pair of eyes on your plan? Share your three numbers, breakeven month, coverage ratio, runway change, and we’ll connect you with experienced consultant.

This article is for general information only and does not constitute financial, legal or tax advice.

FAQs

How much equity do angels usually take?
It varies by deal and stage; angels typically take a minority stake in exchange for capital and support.

What is non‑dilutive funding?
It raises capital without issuing shares. You repay from cash flow or from confirmed sources such as R&D credits or grants.

Will a term loan affect a future equity round?
A sensible facility can extend runway and support growth metrics. Investors focus on traction and debt coverage rather than the presence of a well‑structured loan.

How fast can I access non‑dilutive funding?
Timelines vary by route and documentation; good prep shortens the path to drawdown.

Can I combine angels with non‑dilutive funding?
Yes, many teams blend routes. You can use non‑dilutive capital to de‑risk delivery while you finalise an equity round.

Is grant advance only for Innovate UK awards?
Innovate UK is a common use case, and the approach can work with other awarded programmes that use milestone drawdowns.

Does an R&D advance reduce my HMRC claim?
No. The advance bridges timing. Keep records tight and align with your adviser’s claim process.

venture debt

SPRK Capital Announces New Product Launch and Follow-On Capital Raise

/in /by

SPRK Capital

SPRK Capital, the leading provider of non-dilutive finance to SMEs in the innovation sector, is excited to announce the launch of the SPRK Innovation Term Loan and the closing of its latest capital raise.

Following the successful £3.5m capital raise in June 2023, SPRK has secured an additional £1.5m to further fund the expansion of its loan book growth, providing support to its senior lending facility, as it launches the new SPRK Innovation Term Loan product.

SPRK currently provides finance to SMEs through its SPRK R&D Advance and SPRK Grant Advance solutions. These funding options help businesses manage their cashflow requirements by advancing both R&D and Grant payments to when they’re needed most… now. SPRK has provided loans and facilities from £50,000 to £10m at the lowest cost available in the innovation lending market.

The new Innovation Term Loan expands SPRK’s market-leading lending propositions to provide a new innovative and flexible funding solution to SMEs engaged in innovation, enabling companies to pre-fund their R&D expenditure.

The SPRK Innovation Term Loan lends up to 150% of a company’s most recent R&D claim through a fixed rate, fixed term, amortising loan, enabling access to growth capital to power UK-led innovation. With founder friendly terms and no dilution, this new product seeks to fill the funding gap between traditional shorter-term R&D lending and dilutive, longer term Venture Debt.

Companies make one fixed monthly repayment through the life of the loan and make automatic overpayments, without fees, from their R&D tax credits, helping them plan and invest in growth.

Dominick Peasley, CEO SPRK said, “The Government is committed to making the UK a science superpower. Access to capital for companies engaged in UK-led innovation continues to constrict these growth targets.

The launch of the SPRK Innovation Term Loan looks to address the issues that growing companies have with access to affordable growth finance. For the first time, SMEs engaged in innovation have access to non-dilutive debt finance over a 36-month term, enabling them to plan their R&D effectively with certainty of finance.

We’ve seen an incredible amount of demand for this funding solution and we continue to receive the unwavering support of our investors, debt providers, and trusted advisors and accountancy firm partners as we introduce this groundbreaking offering to the market.”

 

About SPRK:

SPRK provides SMEs engaged in UK-led innovation the ability to release capital from their eligible R&D and Grant spend using its proprietary online platform, ensuring credit decisions are made swiftly with certainty of funding.

Providing loans and facilities of up to £10m+, SPRK’s unique proposition is designed to optimise cashflow for borrowers through a non-dilutionary source of capital with market leading founder-friendly terms.

SPRK offers the ability for companies to borrow against their eligible R&D spend at any point in their financial year, fund their future investment in innovation and advance fund their innovation grant expenditure.

SPRK’s investment in technology combined with institutional funding enables it to remain at the forefront of UK-led innovation finance.

 

Enquiries:

Sprk Capital
Dominick Peasley, CEO
T: 0800 0025 100
www.sprkcapital.co.uk

Interested in finding out more about how SPRK could benefit your business?
We’re local and always keen to connect and discuss how we can help you meet the needs of your business.